{
    "clinical_study": {
        "@rank": "165081", 
        "arm_group": [
            {
                "arm_group_label": "50 mg", 
                "arm_group_type": "Experimental", 
                "description": "50 mg 3 times weekly"
            }, 
            {
                "arm_group_label": "400 mg", 
                "arm_group_type": "Experimental", 
                "description": "400 mg 3 times weekly"
            }, 
            {
                "arm_group_label": "200 mg", 
                "arm_group_type": "Experimental", 
                "description": "200 mg 3 times weekly"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo comparator associated with each active arm. (3:1 active vs placebo)"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical study is investigating AMG 719, an investigational drug, for the treatment of\n      patients who have Rheumatoid Arthritis and who are taking Methotrexate.  AMG 719 is a drug\n      which is self-injected beneath the skin (similarly to the way insulin is self-injected by\n      diabetics). Patients on this study are on study for 28-weeks.  They visit the study facility\n      at least 11 times while participating in the study."
        }, 
        "brief_title": "A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate", 
        "completion_date": {
            "#text": "May 2004", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Men or women, at least 18 years of age at screening\n\n          -  Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks,\n             receiving methotrexate, and having no recent history of substance or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 29, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038298", 
            "org_study_id": "20010238"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo given 3 times weekly", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "50 mg", 
                "description": "50 mg 3 times weekly", 
                "intervention_name": "AMG 719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "200 mg", 
                "description": "200 mg 3 times weekly", 
                "intervention_name": "AGM 719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "400 mg", 
                "description": "400 mg 3 times weekly", 
                "intervention_name": "AMG 719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo dose given 3 times weekly", 
                "intervention_name": "placebo to AMG 719", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "January 20, 2011", 
        "link": [
            {
                "description": "AmgenTrials clinical trials website", 
                "url": "http://www.amgentrials.com"
            }, 
            {
                "description": "Notice regarding posted summaries of trial results", 
                "url": "http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf"
            }, 
            {
                "description": "To access clinical trial results information click on this link", 
                "url": "http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_47_AMG_719_20010238.pdf"
            }
        ], 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of AMG 719 in Subjects With Rheumatoid Arthritis Receiving Methothrexate", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "AMG 719 has a favorable safety profile in subjects with RA receiving methotrexate.", 
            "safety_issue": "Yes", 
            "time_frame": "Week 24"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038298"
        }, 
        "responsible_party": {
            "name_title": "Global Development Leader", 
            "organization": "Amgen Inc."
        }, 
        "secondary_outcome": {
            "measure": "To assess the effects of multiple doses of AMG 719 relative to placebo on signs and symptoms of RA", 
            "safety_issue": "Yes", 
            "time_frame": "Week 24"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2011"
    }, 
    "geocoordinates": {}
}